Stock Monitor: Albireo Pharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Zosano Pharma Corp. (NASDAQ: ZSAN) ("Zosano"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=ZSAN as the Company's latest news hit the wire. On March 16, 2018, the clinical stage Biopharmaceutical Company, which offers rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, declared an important enrollment milestone in M207-ADAM Study. The Company shared that the 100th patient has been enrolled and received M207 in the long-term safety study for the acute treatment of migraine. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Albireo Pharma, Inc. (NASDAQ: ALBO), which also belongs to the Healthcare sector as the Company Zosano Pharma. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=ALBO
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Zosano Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=ZSAN
M207 for Treatment of Migraines
Migraines are severe, recurring, and painful headaches. As per the American Migraine Association, Migraines affect around 36 million Americans, or approximately 12% of the total population.
Zosano's lead development candidate, M207, has been designed to provide pain relief in the treatment of migraine attacks. M207 is basically Zosano's proprietary formulation of zolmitriptan. It is delivered utilizing the Company's ADAM technology, which comprises titanium micro projections coated with the drug. ADAM technology delivers zolmitriptan by penetrating the stratum corneum, which allows the drug to be absorbed into the microcapillary system of the skin.
M207 Achieved Endpoints in ZOTRIP Trial
In February 2017, Zosano declared that M207 has achieved statistically significant results in the recently completed ZOTRIP trial. The ZOTRIP pivotal efficacy study was a multicenter, double blind, randomized, placebo-controlled, dose-ranging trial comparing three doses (1.0mg, 1.9mg, and 3.8mg) of M207 for a single migraine attack. In this trial, the 3.8mg dose met its secondary endpoints of pain freedom at 45 minutes and 1 hour and showed durability of effect on pain freedom at 24 and 48 hours.
M207 ADAM Study Design
M207-ADAM is an open label study that aims to assess the safety of 3.8mg dose of zolmitriptan in migraine patients who have historically experienced at least 2 migraines per month. It must be noted that patients enrolled in this study, are expected to treat a minimum of two migraines per month, with no limits for maximum treatments.
In this study, Zosano plans to evaluate a minimum of 150 patients for six months, and 50 patients for a year at nearly 31 sites in the US. In fact, the Company may even choose to enroll more than the required number of patients. This would help Zosano guarantee a robust data set and achieve the requisite number of evaluable patients completing 6 and 12 months.
Study Objective and Major Updates
The primary aim of the M207-ADAM study is to evaluate the safety of repetitive usage of M207 over 6 and 12 months. The main updates about the study are given below:
- So far, a total of 103 patients have qualified and received the study drug.
- In addition to that, 77 other patients have signed consents and are enrolled in the 2-week run-in evaluation period.
- The patients in this study have treated 278 migraines since initiation.
Study Completion Expected by the End of the Year
Dr. Donald Kellerman, Zosano's Vice President - Clinical Development and Medical Affairs, stated his pleasure on the study's progress. He acknowledged that the clinical investigators are working well on patient recruitment and follow-up. He believes that the enrollment of the 100th patient is an important milestone in the M207-ADAM study.
The clinical investigators will continue enrollment to reach a sufficient number of patients so that about 150 patients complete six months. However, the clinical completion of the study will happen only after 50 subjects have completed a year. Dr. Kellerman was positive that by the end of the year, at least 50 of these patients will complete the study and will have treated at least two migraines per month.
Improved Investor Sentiment
The announcement about 100th patient enrollment in the M207-ADAM study went well with Zosano's investors as it takes the Company one step closer to the development of M207. Zosano's shares were up 14% premarket on the day of announcement.
Stock Performance Snapshot
March 19, 2018 - At Monday's closing bell, Zosano Pharma's stock declined 4.53%, ending the trading session at $16.65.
Volume traded for the day: 524.70 thousand shares.
Stock performance in the last month - up 287.21%; previous three-month period - up 24.25%; and year-to-date - up 60.10%
After yesterday's close, Zosano Pharma's market cap was at $29.14 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
